Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | PREP | P48147 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5152864 | 1.00 | CHRM2 (0.47) | CHRM2CHRM1CHRM3HSD17B10ACE | |
| SCHEMBL646565 | 1.00 | CHRM2 (0.47) | CHRM2CHRM1CHRM3HSD17B10ACE | |
| SCHEMBL6567834 | 1.00 | CHRM2 (0.47) | CHRM2CHRM1CHRM3HSD17B10ACE | |
| SCHEMBL29050069 | 1.00 | CHRM2 (0.47) | CHRM2CHRM1CHRM3HSD17B10ACE | |
| SCHEMBL627476 | 1.00 | CHRM2 (0.47) | CHRM2CHRM1CHRM3HSD17B10ACE | |
| SCHEMBL192488 | 1.00 | CHRM2 (0.47) | CHRM2CHRM1CHRM3HSD17B10ACE | |
| SCHEMBL20348248 | 1.00 | CHRM2 (0.47) | CHRM2CHRM1CHRM3HSD17B10ACE | |
| SCHEMBL1294140 | 1.00 | CHRM2 (0.47) | CHRM2CHRM1CHRM3HSD17B10ACE | |
| SCHEMBL5955704 | 0.90 | ACE (0.51) | CHRM2CHRM1CHRM3HSD17B10ACE | |
| SCHEMBL18018402 | 0.90 | ACE (0.51) | CHRM2CHRM1CHRM3HSD17B10ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688776-A1 | 1-H-PYRROLO[2,3-C]PYRIDINE COMPOUNDS ACTING AGAINST CANCER VIA AGONISM OF MENIN | Acerta Pharma B.V. (NL) | 2026-02-11 | — | — | EP | disclosed |
| US-12358886-B2 | Heterocyclic compounds for use in the treatment of cancer | ARTIOS PHARMA LIMITED (GB) | 2025-07-15 | — | — | US | disclosed |
| CN-114667167-B | Heterocyclic compounds for the treatment of cancer | 阿提奥斯医药有限公司 | 2024-12-20 | — | — | CN | disclosed |
| WO-2024201240-A1 | 1-H-PYRROLO[2,3-C]PYRIDINE COMPOUNDS ACTING AGAINST CANCER VIA AGONISM OF MENIN | ACERTA PHARMA B.V. (NL) | 2024-10-03 | — | — | WO | disclosed |
| CN-118715012-A | Pyrazolopyridine derivative and application thereof in medicine | 西藏海思科制药有限公司 | 2024-09-27 | — | — | CN | disclosed |
| EP-4430035-A1 | SELECT KRAS G12C INHIBITORS AND USES THEREOF | 1200 Pharma LLC (US) | 2024-09-18 | — | — | EP | disclosed |
| CN-118525022-A | Azacyclo derivative and application thereof in medicine | 西藏海思科制药有限公司 | 2024-08-20 | — | — | CN | disclosed |
| CN-118373824-A | Substituted quinazoline-4-ketone compound and preparation method and application thereof | 成都赜灵生物医药科技有限公司 | 2024-07-23 | — | — | CN | disclosed |
| WO-2024133560-A1 | IMIDAZO[1,2-A]PYRIDINE AND IMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS MLLT1 AND MLLT3 INHIBITORS | DARK BLUE THERAPEUTICS LTD (GB) | 2024-06-27 | — | — | WO | disclosed |
| CN-113512042-B | Substituted quinazoline-4-ketone compound and preparation method and application thereof | 成都赜灵生物医药科技有限公司 | 2024-06-11 | — | — | CN | disclosed |
| WO-2008046527-A1 | ACYLAMINOPYRAZOLES FOR TREATING CARDIOVASCULAR DISEASES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-04-24 | — | — | WO | disclosed |
| WO-2008043533-A2 | ACYL AMINOIMIDAZOLES AND ACYL AMINOTHIAZOLES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-04-17 | — | — | WO | disclosed |
| WO-2007082666-A1 | ACYLAMINOIMIDAZOLES | BAYER HEALTHCARE AG (DE) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007082666-A1 | ACYLAMINOIMIDAZOLES | BAYER HEALTHCARE AG (DE) | 2007-07-26 | — | — | WO | disclosed |
| US-20070054909-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-7179819-B2 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
| US-20040229858-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-11-18 | — | — | US | disclosed |
| US-6756378-B2 | BENZYL -UREA, -THIOUREA, OR -GUANIDINE DERIVATIVES THAT INHIBIT THE BINDING OF LIGANDS TO ALPHA 4 BETA 1 INTEGRIN (VLA-4) | PHARMACOPEIA DRUG DISCOVERY, INC. | 2004-06-29 | — | — | US | disclosed |
| US-20030078249-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-04-24 | — | — | US | disclosed |
| CN-1391473-A | VLA-4 inhibitor compounds | DAIICHI SEIYAKU CO (JP) | 2003-01-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078249-A1 | VLA-4 inhibitor compounds | VCAM1, ICAM1, ITGA4 | CHRM2 2236/4885CHRM1 1416/4885CHRM3 2033/4885 |
| US-20070054909-A1 | VLA-4 inhibitor compounds | VCAM1, ITGB4, ICAM1 | CHRM2 1982/4885CHRM1 1248/4885CHRM3 1817/4885 |
| US-20040229858-A1 | VLA-4 inhibitor compounds | VCAM1, ICAM1, ITGB4 | CHRM2 2195/4885CHRM1 1403/4885CHRM3 2018/4885 |
| US-12358886-B2 | Heterocyclic compounds for use in the treatment of cancer | SDHA, DPYD, TP53 | CHRM2 4373/4885CHRM1 3920/4885CHRM3 3594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.